Background: Osteoporosis is the most prevalent skeletal disorder, characterized by a low bone mineral density (BMD) and bone structural deterioration, leading to bone fragility fractures. Accelerated bone resorption by osteoclasts has been established as a principal mechanism in osteoporosis. However, recent experimental evidences suggest that inappropriate apoptosis of osteoblasts/osteocytes accounts for, at least in part, the imbalance in bone remodeling as occurs in osteoporosis. The aim of this study is to examine whether aspirin, which has been reported as an effective drug improving bone mineral density in human epidemiology studies, regulates the balance between bone resorption and bone formation at stem cell levels.
Introduction
Osteoporosis is the most prevalent skeletal disorder, characterized by a low bone mineral density (BMD) and structural deterioration of bone tissue, leading to bone fragility fractures [1] . Postmenopausal osteoporosis is the most common and significant form of osteoporosis in which estrogen deficiency gives rise to a high turnover rate in bone metabolism, as characterized by a over-activated osteoclast activity and a temporal increase in osteoblast activity that is not able to balance osteoclast-mediated bone resorption [1] . Although many systemic and local regulators are involved in estrogen-deficient osteoporosis, it appears that activated T lymphocyte associated osteoclast over-activation play a pivotal role in postmenopausal osteoporosis [2] [3] [4] . Clinically, bisphosphonates are widely used and appear to ameliorate the effects of osteoporosis by inhibiting osteoclast functions. However, recent experimental evidences suggest that bisphosphonates may also inhibit apoptosis of both osteocytes and osteoblasts [5] and increase the bone forming potential of osteoblasts [6] , implying that BMMSC/osteoblast lineage cells may actively participate in the recovery of osteoporosis.
BMMSCs are multipotent postnatal stem cells that are capable of differentiating into osteoblasts, chondrocytes, adipocytes, cardiomyocytes, and myoblasts [7] [8] [9] . It is known that osteoblasts form new bone matrix to balance osteoclast-mediated bone resorption during the bone remodeling process so as to maintaining homeostasis of the bone/marrow system [10] . The interplay between the BMMSC/osteoblast lineage and hemato-poietic stem cells (HSCs) has been reported to play a critical role in regulating the immune system [11] . For instance, cultureexpanded BMMSCs are capable of treating T-cell-associated disorders, such as acute graft-versus-host-disease (GVHD) through inhibiting T lymphocyte proliferation and activity [11] [12] [13] . A recent convergence of clinical and basic research has highlighted a potential link between osteogenic cell death and osteoporosis [14, 15] . It has been suggested that inappropriate apoptosis of osteoblasts/osteocytes accounts for, at least in part, the imbalance in bone remodeling as occurs in osteoporosis, although the elevated activity of osteoclasts is currently thought to be a dominant factor [16, 17] .
The objective of this study was to investigate the effects of activated T cells on BMMSCs in the OVX-induced osteoporosis and examine whether aspirin, which has been identified as an effective drug capable of improving bone mineral density in human epidemiological studies [18, 19] , cures the OVX-induced osteoporosis via regulating BMMSC function.
Materials and Methods

Antibodies
Rat anti-mouse CD3 IgG 3 , anti-mouse CD25 IgM, FITC-or PE-conjugated rat anti-mouse CD25 IgG 1 , FITC-, PE-or PerCPconjugated rat anti-mouse CD4 IgG 2a , and PE-conjugated rat anti-mouse CD45R/B220 IgG 2a were purchased from BD Bioscience. Rabbit anti-human Runx2 IgG was from Oncogene. Rabbit anti-human alkaline phosphatase (ALP) (LF47) and antihuman osteocalcin (OCN) (LF32) were kindly provided by Dr. Larry Fisher (National Institute of Dental and Craniofacial Research, National Institutes of Health). Mouse anti-human bactin IgG was purchased from Sigma-Aldrich Co.
Animals
C3H and C3MRL-Fas lpr mice were purchased from Jackson Lab. The generation of ovariectomy (OVX) mice was performed the same as described previously [20] . Anti-CD25 antibody (1 mg/mouse, R&D system) was injected intraperitoneally into 3-month-old mice at 2 days prior to the OVX procedure. CD4
) and CD4
CD45RB
2/low ( 1610 6 ) T cells isolated from spleen of C3H mice by flow cytometry were injected into the tail vein of immunocompromised mice (bg-nu/nu-xid, Harlan Sprague Dawley Inc.). Aspirin (0.6 mg/ml, Sigma-Aldrich Co) dissolved in water to feed mice for two months before OVX procedure. These animal experiments were performed under an institutionally approved protocol for the use of animal research (USC #10874 and NIDCR #03-277).
Mouse Bone Marrow Mesenchymal Stem cell (BMMSC) culture
Mouse bone marrow cells (10-20610 6 ) harvested from long bones were seeded into 100 mm culture dishes (Corning Costar Co.), incubated for 3 hours at 37uC to allow attachment of adherent cells, and then rinsed twice with PBS to remove the nonadherent cells. Bone marrow cells (10-20610 6 ) from long bones of guinea pigs were then added into each dish as feeder cells. To prevent proliferation in culture, the feeder cells were c-irradiated (Caesium-137) with 6,000 cGy by a Gammacell-1000 Irradiator (Atomic Energy of Canada. Ltd.). BMMSCs formed adherent colonies following 12-15 days culture. Primary cultures were passed to disperse the colony-forming cells (passage 1). The cells at passage 1 at ,70% confluence were utilized for the experiments. Culture medium consisted of a-MEM (Invitrogen Corp.), 20% fetal bovine serum (FBS; Equitech-Bio Inc.), 2 mM L-glutamine, 100 U/ml penicillin / 100 mg/ml streptomycin (Biofluids Inc), and 55 mM 2-mercaptoethanol (2-ME). For the osteogenic induction in vitro, 2 mM b-glycerophosphate (Sigma-Aldrich Co.), 100 mM L-ascorbic acid 2-phosphate (Wako Pure Chemical Industries Ltd.) and 10 nM dexamethasone (Sigma-Aldrich Co.) were added into the culture for 6 weeks.
Human BMMSC culture
Human bone marrow aspirates from healthy human adult volunteers (20-35 years of age) were purchased from AllCells LLC and cultured as reported previously [21] . Single cell suspensions (1-100610 3 /well) of BMMSCs were cultured in 6-well plates (Corning Costar Co.) with ã -MEM supplemented with 15% FBS, 100 mM L-ascorbic acid 2-phosphate, 2 mM L-glutamine, and 100 U/ml penicillin / 100 mg/ml streptomycin. After aspirin was added at 2.5 mg/ml and 50 g/ml for 3-7 days, BMMSCs were induced for osteogenic differentiation with additional 1.8 mM KH 2 PO 4 and then harvested for Western blot analysis.
Isolation and culture of lymph node (LN) and spleen cells
Lymph nodes were collected from axillary and submandibular regions of mice. The LN cells (1.0-2.0610 6 ) were cultured with or without plate-bounded 1 mg/ml anti-CD3 antibody and 1 mg/ml soluble anti-CD28 antibody (BD Bioscience) in complete DMEM containing 10% FBS for 3 days. The culture supernatant was collected and enrichment 10 times to use as a conditioned media (CM).
Co-culture mouse BMMSCs with LN cells
Mouse BMMSCs (200610 3 /well) were plated in 24-well flatbottom plates (Corning Costar Co.), and cultured in mouse BMMSC medium for 3 days. Mouse LN cells isolated from C3H or immunocompromised mice (1610 6 /well) were loaded directly on mouse BMMSC culture or separated from mouse BMMSCs using Transwell system (Corning Costar Co.). The co-culture systems were cultured for 3-5 days in DMEM medium. Some of the co-cultures were treated with 1 mg/ml anti-interferon c (IFNc) antibody, 1 mg/ml anti-tumor necrosis factor a (TNFa) antibody, 1 mg/ml anti-Fas ligand (FasL) antibody (eBioscience or Biolegend), 10 mM brefeldin A (Sigma-Aldrich Co.), 100 nM concanamycin A (Sigma-Aldrich Co.). The cultures were washed to remove LN cells and stained with solution containing 2% paraformaldehyde and 2% toluidine blue or by using an ApopTagH Peroxidase In Situ Apoptosis Detection kit (Chemicon International, Millipore) to detect apoptotic cells.
Cell viability assay
Cell viability was assayed using Cell Counting Kit-8 (Dojindo) according to the manufacturer's protocol.
Transplantation of BMMSCs into immunocompromised mice
Approximately 4.0610 6 of mouse BMMSCs were mixed with 40 mg of hydroxyapatite/tricalcium phosphate (HA/TCP) ceramic powder (Zimmer Inc.) and then transplanted into the dorsal surface of 10-week-old immunocompromised mice as previously described [20, 21] . These procedures were performed in accordance to specifications of an approved small animal protocol (USC#10874). The transplants harvested at 8 weeks posttransplantation were fixed in 4% paraformaldehyde and then decalcified with 10% EDTA (pH 8.0) for paraffin embedding. Paraffin sections were deparaffinized, rehydrated, and stained with hematoxylin and eosin (H&E). For quantification of new bone regeneration in vivo, the NIH image software Image J was used as previously described [20] .
Bone analyses by micro-computed tomography (microCT) and peripheral quantitative CT (pQCT) Distal femoral metaphyses were analyzed by microCT (mCT-20; SCANCO USA, Inc.). Scanning regions were confined to secondary spongiosa and were ,0.30 mm in thickness. Using 2-dimensional images, a region of interest was manually drawn near the endocortical surface. Cancellous bone morphometric indices, assessed using 3-dimensional image reconstructions, included bone volume relative to tissue volume (BV/TV, %), trabecular thickness (Tb.Th), trabecular number (Tb.N) and trabecular separation (Tb.Sp). pQCT analysis of the distal femora was performed using a XCT Research M (Stratec; Norland Co.) as previously described [20] . Briefly, scans were obtained at 2.25 and 2.75 mm from the distal condyles and cancellous BMD. Machine cancellous BMD precision (based on manufacturer data) is 63 mg/cm 3 while the coefficient of variation in our laboratory based on repeat scans was 2.26%.
Colony forming Unit fibroblasts (CFU-F) assay
The CFU-F assay was performed as previously described [20] . Cell aggregates containing more than 50 cells were counted as colonies using a dissecting microscope. The CFU-F assay was repeated in 5 independent experiments.
Cell proliferation assay
The proliferation of BMMSCs was assessed by bromodeoxyuridine (BrdU) incorporation of the cells by using a BrdU staining kit (Invitrogen Co.) as previously described [20] . To quantify cell proliferation capacity of the cells, ten representative images were used to BrdU-positive cell number. Cell proliferation was shown as a percentage of BrdU-positive cells over total nucleated cells.
In vitro mineralization assay
After 6 weeks culture of BMMSCs under osteogenic inductive condition, calcium deposits were detected by staining with 1% alizarin red (Sigma-Aldrich Co.). The mineralized area were quantified by using NIH image Image-J, and shown as a percentage of alizarin red-positive area over total area as previously described [20] .
Flowcytometric analysis
Cells isolated from mouse blood or spleen were incubated with 1 mg of FITC-or PE-conjugated mAbs for 45 min at 4uC. Isotypematched FITC-or PE-conjugated IgG were used as controls. After being washed with PBS/0.4%BSA for 3 times, the cells were analyzed by FACS calibur (Becton Dickinson) for analysis. CD4-positive cells were also sorted before flowcytometric analysis.
Telomerase activity
Telomerase activity in BMMSCs was detected by using a quantitative telomerase detection (QTD) kit (Allied Biotech, Inc.) according to the manufactures' protocol for real-time polymerase chain reaction (PCR) detection. Briefly, cell extraction was prepared from human BMMSCs (100610 ), mixed with 26QTD pre-mix containing telomere primers (TTAGGG) and iQ SYBR green supermix (BioRad Laboratories), and amplified with an iCycler iQ real-time PCR machine (BioRad Laboratories). The generated PCR products are directly detected by measuring the increase in fluorescence caused by binding of SYBR Green to double-strand DNA and calculated by using an iCycler iQ software (BioRad Laboratories). Some cell extract was heated at 85uC for 10 min and used for negative control. The real-time PCR condition was as follows; telomerase reaction for 20 min at 25uC, PCR initial activation step for 3 min at 95uC, 3-step cycling; denaturation for 10 sec at 95uC, annealing for 30 sec at 60uC, extension for 3 min at 72uC, and cycle number 40 cycles.
Measurement of telomere length
Telomere length of human BMMSCs was measured using TeloTAGGG Telomerer Length Assay kit (Rosch, Inc.) according to the manufacturer's protocol. Briefly, genomic DNA was isolated from aspirin (0, 2.5, 50 mg/mL) treated human BMMSCs, enzyme digested and separated on 0.8% agarose gel. Blotting membrane was hybridized with DIG probe followed by anti-DIG-AP and substrate buffer solution, and exposed to X-ray film (Eastman Kodak Co.). NIH image software was used for image analysis. The mean of telomere length was calculated according to manufacturer's instructions 
Western blot analysis
Measurement of receptor activator of NFkB ligand (RANKL), osteoprotegerin (OPG) and C-terminal telopeptides of type I collagen
The blood was collected from retro-orbital venous plexus. Enzyme-linked immunoassay (ELISA) was performed to detect RANKL, OPG and C-terminal telopeptides of type I collagen in the blood serum by using commercial kits for mTRANS/ RANKL/TNFSF11 Quantikine ELISA, mouse Osteoprotegerin/TNFRSF11B Quantikine ELISA Kits (R&D Systems) and for RatLapsH ELISA kit (Nordic Bioscience Diagnostics A/S), respectively, according to their manufactures' instructions.
Bone analyses by histology
Femurs and Tibiae were fixed with 4% paraformaldehyde, decalcified with 10% EDTA (pH 8.0) and embedded in paraffin. Sections were deparaffinized and stained with hematoxylin and eosin (H&E). Tartrate-resistant acid phosphate (TRAP) staining was performed according to the previous report [22] . For quantification of TRAP-positive cells in the bones, five representative images were analyzed by using an NIH Image-J. The results were shown as the number of TRAP-positive cells per total bone area.
In vitro osteoclast assay
Pre-osteoblasts were isolated from calvariae of 3-day-old mice by sequential digestion with 3 mg/ml collagenase type I (Worthington Biochemical Co.) and 4 mg/ml dispase (Boehringer Mannheim /well) were seeded, 10 ng/ml macrophage colony stimulating factor (R&D Systems) and 10 ng/ml RANKL (Peprotech) were added to the culture for 5-6 days. After TRAP staining, TRAP-positive multinucleated cells (.3 nuclei) were counted as osteoclast-like cells.
Statistical analysis
Student's t-test was used to analyze significance between 2 groups. A P value of less than 0.05 was considered as a significant difference.
Results
Activated T lymphocytes induced BMMSC apoptosis through the Fas/FasL pathway
To determine whether activated T cells directly impinge on BMMSC survival, we used a co-culture system including autologous LN T cells and BMMSCs to assess the effect of T lymphocytes on BMMSCs. When co-cultured with ex vivo expanded BMMSCs, the naïve LN cells were unable to induce BMMSC death in vitro.
However, when LN cells were pre-activated with an anti-CD3 specific antibody, significant amount of cell death occurred in the co-cultured BMMSCs within 12 hours (Fig. 1A) . The LN T cellinduced cell death of BMMSCs required direct cell-cell contact, as BMMSCs co-cultured with T cells in the transwell system failed to manifest detectable cell death (Fig. 1A) . To further confirm that observed BMMSC death was attributed to T cells in LN population, we treated BMMSCs with anti-CD3 antibody pretreated LN cells derived from T cell deficient immunocompromised mice in the same co-culture conditions, and found no significant induction of BMMSC death (Fig. 1B) . Next, we verified that the cell death of BMMSCs was due to apoptosis based on terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) staining (Fig. 1C) and 49,69-diamidino-2-phenylindole (DAPI) staining (data not shown). These data indicated that activated T cells were required to induce BMMSC death. Conversely, conditioned supernatants collected from anti-CD3 antibody treated LN cell cultures did not cause significant BMMSC death (Fig. 1D) , eliminating possibility that soluble factor(s) produced by activated T cells are contributory to cell death of BMMSCs. In support of these observations, inclusion of anti-TNFa and anti-IFN-c neutralized antibodies in the co-cultures failed to prevent and reverse activated T cell-mediated apoptosis of BMMCs, suggesting that TNF-a and IFN-c were dispensable (Fig. 1E) . Significantly, blockage of FasFasL death pathway with either anti-FasL antibodies or a chemical inhibitor, brefeldin A, abrogated LN cell-induced cell death of BMMSCs, indicating the Fas/FasL pathway was critical in the apoptosis of BMMSCs. However, concanamycin A failed to block the activated T cell-induced cell death of BMMSCs (Fig. 1F) , suggesting that the perforine/granzyme pathway was not involved. Indeed, we also found that BMMSCs expressed Fas as determined by Western blot analysis (Fig. 1G ) and agonistic anti-Fas antibody was capable of inducing apoptosis of human BMMSCs in vitro (Fig. 1H) . Also, anti-CD3 antibody stimulated spleen cells were capable of inducing apoptosis of BMMSCs and osteoblast-like MG63 cells (data not shown). Finally, we verified that activated T cells failed to induce apoptosis of BMMSCs derived from CD95-deficient (lpr/lpr) mice (Fig. 1I ).
CD4
+ CD25 2 CD45RB +hi T cell infusion resulted in BMMSC impairment in OVX immunocompromised mice
To examine whether T cell can impair BMMSC in vivo, we adoptively transferred CD4
+hi T cells, previously showed to induce inflammatory bowel disease (IBD) in nude mice [23] and in patients with IBD associated osteoporosis [24, 25] , into OVX immunocompromised mice that lacked osteoporosis phenotype due to the absence of T lymphocytes ( Fig. 2A) 
CD45RB
2/low T cells from the spleens of C3H mice (Fig. 2B) and intravenously infused into immunocompromised mice. One month after the infusion, the typical trabecular bone resorption and lumbar BMD reduction were observed in OVX-immunocompromised mice that received CD4
+hi T cells, but not CD4
2/low T cells (Fig. 2C) , suggesting that CD4
+hi T cells were responsible, at least in great part, for T-cell-associated osteoporosis. Next, we assessed whether 
+hi cell-treated OVX-immunocompromised mice compared to the un-treated or CD4
2/low T cell-treated OVX-immunocompromised animals (Fig. 2D) 
+hi T cell-treated OVX-immunocompromised mice was also dramatically increased compared to the other two groups, as assessed by the BrdU incorporation assay (Fig. 2E) . Moreover, we found that the systemic infusion of CD4
+hi T cells led to an impaired osteogenic differentiation of BMMSCs, as shown by decreased mineralization accumulation in osteogenic inductive cultures (Fig. 2F) and reduced bone formation when transplanted subcutaneously into immunocompromised mice (Fig. 2G) . It is known that elevated osteoclast activity plays a major role in osteoporosis. Here we found that the number of TRAP-positive osteoclasts was significantly increased in CD4
+hi T cell-treated OVX-immunocompromised mice compared to the control groups (Fig. 2H) . Taken together, the data indicated that both impaired BMMSCs and activated osteoclast activity in CD4
+hi T celltreated OVX-immunocompromised mice contributed to the osteoporosis phenotype.
Aspirin recovered OVX-induced osteoporosis by improving osteogenesis and inhibiting osteoclastogenesis
It was known that aspirin improves bone density in aged population [18, 19] , therefore, we examined whether aspirin affects Fas-induced BMMSC apoptosis and found that indeed aspirin is capable of inhibiting Fas antibody-induced cell death of BMMSCs (Fig. 3A) and specifically inducing death of activated T cells ( Fig. 3B and 3C) . To elucidate the role of aspirin in osteoporosis treatment, we used OVX mice treated with low dose aspirin for three months (Fig 3D) . Using microQCT analysis we found that aspirin treatment significantly improved trabecular and cortical bone density in OVX mice (Figs. 3E-3G ). In addition, aspirin treatment suppressed OVX-induced high number of CFU-F and proliferation rate of BMMSCs (Figs. 3H and 3I ). When BMMSCs were transplanted into immunocompromised, the aspirin treated mice showed elevated bone-forming capacity (Fig. 3J) . To further examine the mechanism of aspirin-mediated improvement of osteogenesis, we revealed that aspirin treatment was capable of promoting mineral accumulation of human BMMSCs in osteoinductive cultures (Fig. 3K ) and significantly increased bone formation when these BMMSCs were subcutaneously transplanted into immunocompromised mice (Fig. 3L) . Previously, it was reported that telomerase activation in BMMSCs improves osteogenesis and adipogenesis [21] . Thus, we examined whether aspirin treatment elevated telomerase activity in BMMSCs as seen in epithelial cells [26] . As expected, we found that aspirin treatment slightly raised telomerase activity in BMMSCs (Fig. 3M) and their telomere lengths (Fig. 3N) . The underlying mechanisms of aspirin effect on bone metabolism appear to correlate with increased expression of certain osteogenic genes including Runx2, a master gene for osteogenic differentiation, ALP, and OCN (Fig. 3O) . Additionally, ex vivo aspirin treatment was capable of accelerating degradation of phospho-b-catenin (Fig. 3P ), resulting in an increased level of WNT signaling, a recognized pathway in osteogenesis. Since a balance between bone formation and resorption is required for maintaining bone integrity in the remodeling process. We further examine the role of aspirin on osteoclast activity and found that long-term aspirin treatment can systemically alter several serum markers, reduced RANKL and increased OPG in OVX mice (Fig. 4A) . Although we found a decreased level of C-terminal telopeptide in aspirin treated OVX mice, it failed to show a statistically significant difference (Fig. 4A) . Histological sections showed a marked decrease in TRAP-positive cells in the tibia of aspirin treated OVX mice in comparison to the OVX and sham mice (Fig. 4B) . Further studies using osteoclast progenitors derived from the bone marrow and spleen co-cultured with pre-osteoblasts from calvariae revealed that TRAP-positive multinucleated cells (TRAP + -MNCs) significantly decreased in the aspirin-treated group in a dose-dependent manner (Fig. 4C) . Additionally, ex vivo aspirin treatment can block RANKL-induced osteoclastogenesis (Fig. 4D) . Taken together, these data indicated that aspirin is capable of improving bone formation and inhibiting bone resorption through multiple mechanisms.
Discussion
Aspirin may contribute to multiple biological pathways, such as inhibiting COX2 and COX1, and PG2 activities. This makes it difficult to elucidate the detailed functional mechanism of aspirin in relation to bone remodeling. Epidemiological studies reported that the regular use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) may have a moderate beneficial effect on BMD in postmenopausal woman [18] , however, there appears no clinically significant protective effect on the subsequent risk of fractures [19] . This discrepancy may be linked to the multiple functional roles of aspirin where its activity may largely depend on the in vivo microenvironment. Moreover, diversified functional roles of aspirin make it unlikely that any single pathway contributes solely to its anti-apoptotic effect on BMMSCs. In this study, we found that aspirin was able to up-regulate telomerase activity as seen in other cell types [26] with capability to increase bone formation [21] . We speculate that up-regulated telomerase activity in BMMSCs resulted in aspirin-mediated osteogenesis, suggesting that aspirin could serve a potential treatment of osteoporosis in the OVX mice. Aspirin-elevated telomerase level in BMMSCs is much lower than that in cancer cells, implying a safe use of aspirin to improve osteogenesis.
Although it has been proposed that anti-osteogenic cell apoptosis or improved osteogenic cell function is an effective approach for osteoporosis treatment [27] as occurs with the application of PTH [28] , simultaneously targeting of osteoclasts and osteoblasts to treat osteoporosis may be a more potent therapeutic approach. Despite the fact that well-developed antiosteoclast drugs, such as bisphosphonates and strontium, have achieved reasonable therapeutic effects in osteoporosis patients [29, 30] , their functions may also involve an independent effect on improving osteogenic cell function [6, 31] . More importantly, it is necessary to examine whether this combination therapy is a superior choice for the treatment of osteoporosis than the currently available therapeutic regimen.
It has been reported that the adoptive transfer of T cells can restore OVX-induced bone loss in nude mice [32] . Transfer of CD4 + CD45RB +hi T cells to immune-deficient recipients leads to the development of IBD [23, 33] . In contrast, transfer of the reciprocal CD4 + CD45RB 2/low population not only failed to induce colitis, but also prevented it [34] . Interestingly, patients with IBD often have decreased bone mass, an increased risk of developing osteoporosis, and associated fragility fractures and morbidity [35, 36] . Although osteoclasts and osteoblasts are suspected to be involved in the low bone mass in IBD patients, the precise mechanisms of action remain unclear, especially whether activated T cells act on osteogenic progenitor cells is currently unknown. Therefore, in this study we applied a widely used T-cell adoptive transfer system in mice to elucidate the association between CD4 + CD45RB +hi T cells and BMMSCs, adding a potential mechanism that may contribute to the bone phenotype in osteoporosis patients. More importantly, we provided direct evidences to support the notion that interplays between T cells and BMMSCs through Fas/FasL signaling pathway may be critical for pathogenesis of osteoporosis.
The Fas/FasL system is a physiologically important pathway for the regulation of tumor cell proliferation and suppression of immune response. Deregulation of Fas/FasL leads to various severe clinical disorders associated with uncontrolled T cell proliferation, such as organ transplantation graft rejection, systemic lupus erythematosus, Sjogren's syndrome, and lymphoid tumors [37] . FasL was originally discovered on cells of the lymphoid/myeloid lineage, including activated T cells, where it plays an important role in immune homeostasis and T cell-and NK cell-mediated toxicity [38] . Expression of FasL in activated T lymphocytes plays an important role in Fas-mediated tumor killing. It has been reported that osteoblasts express Fas and the FasL/Fas pathway involved in osteogenic cell apoptosis in response to glucocorticoids [39] . Here, we found that BMMSCs are akin to osteoblasts expressing Fas. In our study, activated T lymphocytes can trigger BMMSC apoptosis, predominantly through the FasL/Fas pathway, supporting the notion that Fas antigen is involved in BMMSC death in vivo [40] . In contrast, the perforin-based pathway, another major mechanism of cellmediated cytotoxicity, is not involved in activated T cell-mediated BMMSC apoptosis. In this study, we used LN cells to interact with BMMSCs, where the LN population contains both inflammatory and regulatory T cell populations. Other cell types such as macrophages and dendritic cells (DCs) may participate in T cell activation in our co-culture system. Further studies are needed to determine whether and how each subset of T cell affects BMMSC apoptosis.
In summary, this study revealed that activated T lymphocytes are responsible for the BMMSC apoptosis through the Fas/FasL pathway, resulting in accelerating osteoporosis phenotype in OVX mice. Moreover, we found that pharmacologic regulation of BMMSCs by aspirin may offer a new approach for estrogendeficient osteoporosis treatment. 
